Company Description
Silo Pharma. Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research.
The company's developing solutions to address various underserved conditions. It also seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the benefits they may have in certain cases involving depression, mental health issues, and neurological disorders.
The company focuses on merging traditional therapeutics with psychedelic research for people suffering from indications, such as depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders.
The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020.
Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.
| Country | United States |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Eric Weisblum |
Contact Details
Address: 677 N. Washington Blvd Sarasota, Florida 34236 United States | |
| Phone | (718) 400-9031 |
| Website | silopharma.com |
Stock Details
| Ticker Symbol | SILO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001514183 |
| CUSIP Number | 82711P102 |
| ISIN Number | US82711P2011 |
| Employer ID | 46-2137136 |
| SIC Code | 2300 |
Key Executives
| Name | Position |
|---|---|
| Eric Weisblum | Chairman, President and Chief Executive Officer |
| Daniel E. Ryweck | Chief Financial Officer |
| Dr. James S. Kuo M.B.A., M.D. | Vice President of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 5, 2024 | 8-K | Current Report |
| Mar 25, 2024 | 10-K | Annual Report |
| Feb 1, 2024 | 8-K | Current Report |
| Jan 30, 2024 | EFFECT | Notice of Effectiveness |
| Jan 25, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Jan 25, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 25, 2024 | UPLOAD | Filing |
| Jan 23, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 11, 2024 | 8-K/A | [Amend] Current report |
| Jan 9, 2024 | 8-K | Current Report |